COVID-19 prognosis with the use of renin-angiotensin-aldosterone system inhibitors

This study was carried out with the aim of expressing the prognosis of COVID-19 with a history of taking drugs affecting the renin-angiotensin system in affected patients.

In this cross-sectional observational-analytical study, the information of patients who were referred to Imam Reza (AS) hospital with suspected symptoms of COVID-19 from March 2018 to May 1400, was extracted from the registry system of Imam Reza (AS) Mashhad Hospital. Demographic information, underlying diseases and simultaneous use of other drugs, drugs used in the treatment of COVID-19, body temperature, blood oxygen level, progression of COVID-19, on the day of admission and the day of discharge in 139 patients with COVID-19 with history of use drugs affecting the renin-angiotensin system in the management of blood pressure (group A) were compared with 67 patients with COVID-19 who had no history of taking drugs affecting the renin-angiotensin system in the management of blood pressure. The duration of hospitalization and the final outcome (improvement/death) were also recorded for the patients.

There was no statistically significant relationship between the history of taking drugs affecting the renin-angiotensin system with the mortality rate (p=0.72) and clinical parameters such as the severity of the COVID-19 disease (p=0.64), fever (p=0.72) and the level of oxygen in the blood (p=0.40).

The history of taking drugs affecting the renin-angiotensin system does not play a major role in the exacerbation of the disease of COVID-19 or the increase in mortality in patients with hypertension.